Discuss about Vaccine Enhancement of Disease

doi:10.19803/j.1672-8629.2021.04.09

Abstract

Abstract: Vaccine Enhancement of Disease was discussed in this paper, in order to provide information for post-marketing surveillance of SARS-CoV-2 vaccines. Methods The documents and research findings about virus vaccines and vaccine enhancement of disease (VED) were collected to analyze the safety of SARS-CoV-2 vaccines. Results and Conclusion The epidemic caused by SARS-CoV-2 has been spreading globally since 2020. As no wonder drugs are currently available, vaccine development is becoming a hot topic worldwide. Due to its uncertainty, VED is one of the common concerns during vaccine development and post-marketing surveilance should be carefully assessed in the future.

Key words: antibody-dependent enhancement, vaccine enhancement of disease, SARS-CoV-2, SARS-CoV-2 vaccines

CLC Number:

R954.5

WANG Yali. Discuss about Vaccine Enhancement of Disease[J]. Chinese Journal of Pharmacovigilance, 2021, 18(4): 338-340.

References

[1] Bulut C, Kato Y.Epidemiology of COVID-19[J]. Turk J Med Sci, 2020, 21(50): 563-570.
[2] Shi Y, Wang G, Cai XP, et al.An overview of COVID-19[J]. J Zhejiang Univ Sci B. 2020, 21(5): 343-360.
[3] Kang Z, Tang M.Progress and analysis on the development of 2019-nCoV vaccine[J]. China Academic Journal Electronic Publishing House(生物医学工程学杂志).. 2020 ,37(3): 373-379.
[4] Wang Y, Yin HJ, Wang QL, et al.The common problem of COVID-19 vaccines in non-clinical research[J]. Chin J Biologicals July(中国生物制品学杂志), 2020, 33(7): 837-839.
[5] Arvin AM, Fink K, Schmid MA, et al.A perspective on potential antibody-dependent enhancement of SARS-CoV-2[J]. Nature, 2020, 13: 2538-2538.
[6] Huisman W, Martina BEE, Rimmelzwaan GF, et al.Vaccine-induced enhancement of viral infections[J]. Vaccine, 2009, 27(4): 505-512.
[7] Ulrich H, Pillat MM, Tárnok A.Dengue fever, COVID-19 (SARS-CoV-2), and antibody-dependent enhancement (ADE): A perspe-ctive[J]. Cytometry A, 2020, 97(7): 662-667.
[8] Halstead SB.Which dengue vaccine approach is the most promising, and should we be concerned about enhanced disease after vaccination? There is only one true winner[J]. Cold Spring Harb Perspect Biol, 2018, 10(6): a030700.
[9] WHO. Dengue position paper[M/OL]. (2017-09-07) [2020-08-04] https://www.who.int/immunization/policy/position_papers/dengue/en/.(2017-09-07) [2020-08-04].
[10] Prompetchara E, Ketloy C, Palaga T.Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic[J]. Asian Pac J Allergy Immunol, 2020, 38(1): 1-9.
[11] Ma C, Su S, Wang J, et al.From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development[J]. Microbes Infect, 2020, 22(6-7): 245-253.
[12] Smatti MK, Thani AAAl, Yassine HM.Viral-induced enhanced disease illness-mark[J]. Front Microbiol. 2018, 9: 2991.
[13] Yip M S, Leung NHL, Cheung C Y, et al.Antibody-dependent infection of human macrophages by dsevere acute respiratory syndrome coronavirus[J]. Virol J, 2014, 11: 82.
[14] Hotez PJ, Corry DB, Bottazzi ME.COVID-19 vaccine design: the janus face of immune enhancement[J]. Nat Rev Immunol, 2020, 20(6): 347-348.
[15] Yip MS, Leung HL, Li PH, et al.Antibody-dependent enhancement of SARS coronavirus infection and its role in the pathogenesis of SARS[J]. Hong Kong Med J, 2016, 22(3 Suppl 4): 25-31.
[16] Luo F, Liao FL, Wang H, et al.Evaluation of antibody-dependent enhancement of SARS-CoV infection in rhesus macaques immunized with an inactivated SARS-CoV Vaccine[J]. Virol Sin, 2018, 33(2): 201-204.
[17] Lambert PH, Ambrosino DM, Andersen SR, et al.Consensus summary report for CEPI/BC March 12-13, 2020 meeting: assessment of risk of disease enhancement with COVID-19 vaccines[J]. Vaccine, 2020, 38(31): 4783-4791.
[18] Zhang QT, Wang YL, Qu Y.Discussion on vaccine active surveillance in china[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2016, 13(11): 673-675.